Emergent BioSolutions Inc DEFA14A, filed Apr 15, 2022

Emergent BioSolutions Inc. (EBS)

DEFA14A 2022-04-15

Added on October 16, 2026


	(1)	Title of each class of securities to which transaction applies:

	(2)	Aggregate number of securities to which transaction applies:

	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

	(4)	Proposed maximum aggregate value of transaction:

	(5)	Total fee paid:

☐	Fee paid previously with preliminary materials.

☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	(1)	Amount Previously Paid:

	(2)	Form, Schedule or Registration Statement No.:

	(3)	Filing Party:

	(4)	Date Filed:




				Your Vote Counts!
				EMERGENT BIOSOLUTIONS INC. 2022 Annual Meeting Vote by May 25, 2022 11:59 PM ET

EMERGENT BIOSOLUTIONS INC. 400 PROFESSIONAL DRIVE, SUITE 400 GAITHERSBURG, MD 20879










D78311-P67517


Voting Items		Board Recommends

1. 1a.	To elect three Class I directors to hold office for a term expiring at our 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. Nominees Class I: Keith Katkin	For
1b.	Ronald Richard	For

1c.	Kathryn Zoon, Ph.D.	For

2.	To ratify the appointment by the audit committee of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.	For

3.	Advisory vote to approve executive compensation.	For